PO.TB10.02 · 肿瘤生物学

Development of a flow cytometry panel for microglia and immune cell populations in a brain tumor model

海报缩略图:Development of a flow cytometry panel for microglia and immune cell populations in a brain tumor model
编号 6139 展板 30 时间 4/21 02:00–05:00 区域 Section 28 主讲 Helen Ketteringham, BSc, MSc, PhD
分会场 Metastasis and Organ-Specific Microenvironmental Evolution
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Helen Ketteringham1, Cheryl Davis2, Mollie McArthur1, Corrine Silvio3, Shannan Paul3, Ben Hoerner3, Victoria Caruso3, Liz Bailey4, Chris Holding5, Aliccia Koznecki5, Dawn Lusk3, Shorena Nadaraia-Hoke3

1Reaction Biology Corp, Malvern, PA,2Reaction Biology Europe GmbH, Freiburg im Breisgau, Germany,3Reaction Biology Corp, Hummelstown, PA,4Reaction Biology Corp, Boston, MA,5Reaction Biology Corp, Hershey, PA

摘要 Abstract

Accurate characterization of microglia and infiltrating immune cell populations is essential for understanding the immunological landscape of brain tumors and for evaluating therapeutic responses. Here, we report the development and optimization of a multicolor flow cytometry panel tailored to discriminate resident microglia from peripheral myeloid and lymphoid subsets within an experimental brain tumor model. Marker selection was guided by tissue-specific expression profiles, leveraging differential levels of CD45, CX3CR1, and P2RY12 to resolve microglia, while incorporating canonical markers for infiltrating macrophages, dendritic cells, neutrophils, and T cells. Enzymatic dissociation conditions, viability dye selection, and gating hierarchy were systematically optimized to preserve epitope integrity and maximize signal resolution. Validation using tumor-bearing and control brain tissues demonstrated robust separation of microglial and infiltrating populations with reproducible quantification across biological replicates. This workflow provides a reliable and scalable approach for immune profiling in brain tumor research, enabling deeper insight into neuroimmune interactions and immunotherapy-driven changes within the tumor microenvironment.
利益披露 Disclosure
H. Ketteringham, None.. C. Davis, None.

在会议检索中打开